Bahji A, Crockford D, Brasch J, Schutz C, Buckley L, Danilewitz M
Can J Psychiatry. 2024; 69(6):428-456.
PMID: 38613369
PMC: 11107443.
DOI: 10.1177/07067437241231128.
Ingesson-Hammarberg S, Jayaram-Lindstrom N, Hammarberg A
Addict Sci Clin Pract. 2024; 19(1):12.
PMID: 38388959
PMC: 10882804.
DOI: 10.1186/s13722-024-00443-z.
Bobak T, Majer J, Jason L
Alcohol Treat Q. 2023; 41(2):237-249.
PMID: 37274149
PMC: 10237632.
DOI: 10.1080/07347324.2023.2181120.
Gancz N, Forster S
Am J Drug Alcohol Abuse. 2022; 49(1):5-20.
PMID: 36099534
PMC: 9974755.
DOI: 10.1080/00952990.2022.2116712.
Braback M, Brantefors A, Franck J, Bradvik L, Isendahl P, Nilsson S
Int J Environ Res Public Health. 2022; 19(2).
PMID: 35055519
PMC: 8775654.
DOI: 10.3390/ijerph19020697.
An examination of abstinence social support among recovery home residents with psychiatric comorbidity.
Majer J, Jason L, Bobak T
Drug Alcohol Depend. 2021; 228:108971.
PMID: 34508961
PMC: 8595772.
DOI: 10.1016/j.drugalcdep.2021.108971.
A cohort study evaluating the association between concurrent mental disorders, mortality, morbidity, and continuous treatment retention for patients in opioid agonist treatment (OAT) across Ontario, Canada, using administrative health data.
Morin K, Eibl J, Gauthier G, Rush B, Mushquash C, Lightfoot N
Harm Reduct J. 2020; 17(1):51.
PMID: 32703310
PMC: 7376938.
DOI: 10.1186/s12954-020-00396-x.
Convergent Validity of Self-Administered Addiction Severity Index in a Sample of Nigerian Patients in a Residential Treatment Facility.
Yerima M, Onifade P, Wakawa I, Pindar S, Jidda M, Musami U
Niger Med J. 2020; 61(2):73-77.
PMID: 32675898
PMC: 7357803.
DOI: 10.4103/nmj.NMJ_59_19.
Ambivalent attendees: Transitions in group affiliation among those who choose a 12-step alternative for addiction.
Tsutsumi S, Timko C, Zemore S
Addict Behav. 2019; 102:106143.
PMID: 31855782
PMC: 7043797.
DOI: 10.1016/j.addbeh.2019.106143.
Integrating Treatment for Co-Occurring Mental Health Conditions.
Yule A, Kelly J
Alcohol Res. 2019; 40(1).
PMID: 31649837
PMC: 6799972.
DOI: 10.35946/arcr.v40.1.07.
Engagement in treatment for depression among people who inject drugs in Baltimore, Maryland.
Genberg B, Astemborski J, Treisman G, Anagnostopoulos A, Mehta S, Kirk G
J Subst Abuse Treat. 2019; 106:107-112.
PMID: 31540605
PMC: 6800030.
DOI: 10.1016/j.jsat.2019.09.001.
Toward Personalized Tinnitus Treatment: An Exploratory Study Based on Internet Crowdsensing.
Simoes J, Neff P, Schoisswohl S, Bulla J, Schecklmann M, Harrison S
Front Public Health. 2019; 7:157.
PMID: 31294010
PMC: 6604754.
DOI: 10.3389/fpubh.2019.00157.
Understanding the relapse process: exploring Iranian women's substance use experiences.
Khazaee-Pool M, Pashaei T, Nouri R, Taymoori P, Ponnet K
Subst Abuse Treat Prev Policy. 2019; 14(1):27.
PMID: 31215472
PMC: 6582531.
DOI: 10.1186/s13011-019-0216-3.
"I's" on the prize: A systematic review of individual differences in Contingency Management treatment response.
Forster S, DePhilippis D, Forman S
J Subst Abuse Treat. 2019; 100:64-83.
PMID: 30898330
PMC: 7678142.
DOI: 10.1016/j.jsat.2019.03.001.
Rapid Assessment of Nutrition Services in Los Angeles Substance Use Disorder Treatment Centers.
Wiss D, Schellenberger M, Prelip M
J Community Health. 2018; 44(1):88-94.
PMID: 30030681
DOI: 10.1007/s10900-018-0557-2.
Prediction of drug abuse recurrence: a Swedish National Study.
Kendler K, Ohlsson H, Sundquist K, Sundquist J
Psychol Med. 2017; 48(8):1367-1374.
PMID: 28994361
PMC: 5893422.
DOI: 10.1017/S0033291717002938.
The impact of psychopathological subtypes on retention rate of patients with substance use disorder entering residential therapeutic community treatment.
Maremmani A, Pani P, Trogu E, Vigna-Taglianti F, Mathis F, Diecidue R
Ann Gen Psychiatry. 2016; 15:29.
PMID: 27833645
PMC: 5101731.
DOI: 10.1186/s12991-016-0119-x.
The efficacy of behavioural activation treatment for co-occurring depression and substance use disorder (the activate study): a randomized controlled trial.
Ross J, Teesson M, Lejuez C, Mills K, Kaye S, Brady K
BMC Psychiatry. 2016; 16:221.
PMID: 27391675
PMC: 4939012.
DOI: 10.1186/s12888-016-0943-1.
Course of Psychiatric Symptoms and Abstinence among Methamphetamine-Dependent Persons in Sober Living Recovery Homes.
Polcin D, Witbrodt J, Korcha R, Gupta S, Mericle A
J Psychoactive Drugs. 2016; 48(3):173-80.
PMID: 27184803
PMC: 4945390.
DOI: 10.1080/02791072.2016.1180466.
Comparative Analysis of Treatment Conditions upon Psychiatric Severity Levels at Two Years Among Justice Involved Persons.
Majer J, Chapman H, Jason L
Adv Dual Diagn. 2016; 9(1):38-47.
PMID: 27158265
PMC: 4854532.
DOI: 10.1108/ADD-07-2015-0015.